Literature DB >> 8932997

HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM.

D Agardh1, L K Gaur, E Agardh, M Landin-Olsson, C D Agardh, A Lernmark.   

Abstract

Some insulin-dependent diabetic (IDDM) patients develop severe forms of retinopathy. Putative risk factors such as hypertension, poor metabolic control, nephropathy and growth hormone levels do not fully explain the progress of retinopathy in these patients. It has been discussed whether there is a genetic marker, since some diabetic patients without any known predisposing risk factors develop severe retinopathy and others do not. In the present study, HLA-DR and DQ were compared in two patient groups with IDDM. One group consisted of patients with early-onset diabetes, with severe non-proliferative or proliferative retinopathy; the other group had no or only mild signs of retinopathy. High resolution HLA typing was carried out by polymerase chain reaction (PCR) and hybridization with allele specific probes. Alleles on the DR3-DQ2 haplotype, DRB1*0301, DQA1*0501 and DQB1*0201, were more frequent in patients with severe retinopathy. A difference was seen when combining certain alleles in the genotypes of DQA1*03/0501 (p > 0.05) and DQB1*0201/0302 (p < 0.01). The findings of the present study suggest that DQB1*0201/0302 is the strongest genetic marker for severe retinopathy and DRB1*0301/0401 only has a secondary influence when combined with this genotype. It seems as if IDDM patients who are positive for the genotype DR3-DQ2/DR4-DQ8 (DRB1*0301-DQA1*0501-DQB1*0201/DRB1*0401 -DQA1*03-DQB1*0302) are at greater risk of developing severe retinopathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932997     DOI: 10.1007/s001250050575

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  8 in total

1.  HLA typing is not predictive of proliferative diabetic retinopathy in patients with younger onset type 2 diabetes mellitus.

Authors:  T Mimura; S Amano; S Kato; M Araie; H Funatsu; S Kitano; E Shimizu; H Noma; O Yoshino; S Hori
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

2.  Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.

Authors:  T S Kern; C M Miller; J Tang; Y Du; S L Ball; L Berti-Matera
Journal:  Mol Vis       Date:  2010-08-15       Impact factor: 2.367

3.  HLA class I and II alleles are associated with microvascular complications of type 1 diabetes.

Authors:  E M Lipner; Y Tomer; J A Noble; M C Monti; J T Lonsdale; B Corso; W C L Stewart; D A Greenberg
Journal:  Hum Immunol       Date:  2013-01-29       Impact factor: 2.850

Review 4.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

5.  HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later.

Authors:  Richard A Jensen; Elisabet Agardh; Ake Lernmark; Soffia Gudbjörnsdottir; Nicholas L Smith; David S Siscovick; Carina Törn
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

Review 6.  Importance of Autoimmune Responses in Progression of Retinal Degeneration Initiated by Gene Mutations.

Authors:  Grazyna Adamus
Journal:  Front Med (Lausanne)       Date:  2021-12-02

7.  Association between LTA, TNF and AGER polymorphisms and late diabetic complications.

Authors:  Eero Lindholm; Ekaterina Bakhtadze; Corrado Cilio; Elisabet Agardh; Leif Groop; Carl-David Agardh
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

8.  Linkage Analysis of Genomic Regions Contributing to the Expression of Type 1 Diabetes Microvascular Complications and Interaction with HLA.

Authors:  Ettie M Lipner; Yaron Tomer; Janelle A Noble; Maria C Monti; John T Lonsdale; Barbara Corso; David A Greenberg
Journal:  J Diabetes Res       Date:  2015-10-11       Impact factor: 4.011

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.